Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | CCNC | P24863 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286500 | 0.86 | P2RX7 (0.34) | P2RX7SCDSCD5VNN1NAMPT | |
| SCHEMBL18843016 | 0.86 | P2RX7 (0.34) | P2RX7SCDSCD5VNN1NAMPT | |
| SCHEMBL20968873 | 0.84 | P2RX7 (0.34) | P2RX7SCDSCD5VNN1NAMPT | |
| SCHEMBL15505981 | 0.83 | P2RX7 (0.33) | P2RX7SCDSCD5LRRK2ADRA1D | |
| SCHEMBL23073866 | 0.80 | P2RX7 (0.32) | P2RX7SCDSCD5 | |
| SCHEMBL20969052 | 0.76 | CHRM1 (0.33) | P2RX7ADRA1A | |
| SCHEMBL2664632 | 0.75 | SCD (0.36) | P2RX7SCDSCD5VNN1NAMPT | |
| SCHEMBL15697005 | 0.74 | P2RX7 (0.34) | P2RX7SCDSCD5VNN1 | |
| SCHEMBL21672357 | 0.73 | ADRA1A (0.34) | ADRA1A | |
| SCHEMBL13131076 | 0.72 | ATR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2023-08-24 | — | — | US | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298810-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090298810-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| WO-2007124423-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | P2RX7 3045/4885SCD 2290/4885SCD5 2586/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | P2RX7 3197/4885SCD 3811/4885SCD5 4126/4885 |
| US-20230265103-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | P2RX7 2622/4885SCD 2586/4885SCD5 3337/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | P2RX7 34/4885SCD 2388/4885SCD5 1123/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | P2RX7 1713/4885SCD 2624/4885SCD5 2824/4885 |
| US-20090186899-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | P2RX7 130/4885SCD 3968/4885SCD5 4056/4885 |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | P2RX7 191/4885SCD 2181/4885SCD5 2162/4885 |
| US-20090075970-A1 | Thieno-and furo-pyrimidine modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | P2RX7 17/4885SCD 3481/4885SCD5 2797/4885 |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | P2RX7 4428/4885SCD 1144/4885SCD5 1047/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | P2RX7 1701/4885SCD 858/4885SCD5 686/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | P2RX7 4456/4885SCD 752/4885SCD5 826/4885 |
| US-20090298810-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | P2RX7 238/4885SCD 3623/4885SCD5 3467/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | P2RX7 649/4885SCD 3497/4885SCD5 3664/4885 |
| US-20090203672-A1 | Substituted Sulfonamide Compounds | RPS4X, RPS4Y1, CACNA1A | P2RX7 221/4885SCD 3119/4885SCD5 3639/4885 |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | MSR1, FPR2, CD14 | P2RX7 82/4885SCD 1976/4885SCD5 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.